Funding for this research was provided by:
National Institute on Drug Abuse (R44DA04395402)
National Science Foundation (GRFP)
Stanford University (Stanford Bio-X)
Precision Health and Integrated Diagnostics Center at Stanford
Received: 20 November 2020
Accepted: 6 October 2021
First Online: 19 October 2021
: The Stanford University Institutional Review Board reviewed and approved the study (IRB 30205) prior to any human subjects research activities taking place. Informed consent was collected electronically online from the parent/legal guardian of all participants prior to participants completing research activities. The obesity data from a previously published paper, and the data was already made public. [CitationRef removed].
: Not applicable.
: The authors declare a conflict of interest. The authors affiliated with Second Genome, Inc. have the following competing interests: this work was supported by Second Genome Inc. which employs and provides stock options to T.D, and SI. Second Genome Inc. is an independent therapeutics company with products in development to treat human disease. A publication announcing the viability of using sequence-based biomarker analysis for academic use will not affect the value of SG’s therapeutic products. MD has financial interests in/relative to Second Genome, company that could benefit from the conduct or outcomes of this research.